Trial result ·
NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested nicotinamide riboside (NR) in people with mild-to-moderate psoriasis. NR raises NAD+ levels. Earlier lab work showed NR dampened immune responses in T cells from people with psoriasis. This study was randomized and placebo-controlled. Participants took NR (500 mg doses) or a placebo for 4 weeks. Blood was drawn at the start and at the end.
What they found
NR dampened the Th17 immune response. RNA tests of CD4+ T cells showed the SLIT-ROBO pathway switched on. NR raised circulating SLIT2 levels. It also raised SLIT2 production in dermal fibroblasts. In lab tests, SLIT2 acted through the ROBO1 receptor. This lowered Th17 polarization and fibroblast inflammation.
What it means for patients
The authors say NAD+ augmentation has anti-inflammatory effects in psoriasis. They say SLIT2 and ROBO1 link skin fibroblasts with CD4+ T cells in the blood. They say this leads to suppression of Th17-driven inflammation.
Why it is not certain yet
The abstract does not give how many people took part. It does not give skin scores. The findings are about immune mechanisms. They come partly from lab tests on cells.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis.
PubMed · PMID 42048163We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Psoriasis publications